Douglass Given, MD, PhD
Doug is a physician-scientist, executive, serial entrepreneur, and investor. He is the Managing Partner at Health2047 Capital Partners LLC (HCAP) 2018-present. He served as Health2047 lnc. Chief Executive from its founding in 2015 until 2018. The portfolios include a dozen+ company formation startups with seed financing from Health2047 and an additional dozen+ venture investments made by HCAP. The investment themes are: data, productivity, value, and chronic disease. Doug has spent more than two decades in venture capital as an Investment Partner and General Partner at life sciences investor Bay City Capital LLC participating in five sequential life sciences general funds and two sector-specific funds; he was associated with the partnership from 1999-2015. In addition to a number of private companies, he led three successful public biopharmaceutical companies as CEO.
Doug has served on more than 20 public and private boards. He is currently a Director at Health2047 Inc, Board Chair at Arrowhead Pharmaceuticals (NASDAQ:ARWR), Managing Partner at G5 Partners LLC, and serves on the board at First Mile Care Inc, BrYet Health Ltd, Visirna Therapeutics (China), and Vivaldi Biosciences (Vienna and US). He has advised the Queensland Investment Fund(QIC and QBF). He has served in board roles on: the University of Chicago Pritzker School of Medicine, and Biological Sciences Division Council (former Chair); Johns Hopkins Bloomberg School of Public Health, Health Advisory Board; TC Chan Harvard School of Public Health, International Council; Stanford Medicine, Community Council; The Houston Methodist Research Institute; and the Stanford Institute of Economic Policy Research (SIEPR).
Doug received MD and PhD degrees (Virology) from the University of Chicago, an MBA from the Wharton School at the University of Pennsylvania and was a Clinical and Research Fellow in internal medicine and infectious diseases at Massachusetts General Hospital and Harvard Medical School. He has held global corporate and operating executive positions at Lilly, Monsanto, Schering Plough and Mallinckrodt.
Katie Given, MD, MBA, PhD
Dr. Given is double board certified in Dermatology and Micrographic Surgery and Cutaneous Oncology (Mohs Surgery), and is board eligible in Clinical Informatics. She is an honors graduate from the University of Chicago and the Pritzker School of Medicine followed by an Internal Medicine internship at the University of Chicago Hospitals, Dermatology residency at Yale-New Haven Hospitals, where she served as Chief Resident, and Mohs Surgery and Cosmetic Fellowship (injectables, lasers) at University of California, San Francisco. While in training, she was awarded a T32 NIH Postdoctoral Fellowship in Clinical Informatics, and worked with a Melanoma Tumor Board Registry and the Yale New Haven Hospital Center for Outcomes Research and Evaluation (CORE) focusing on database quality and validation. She is actively engaged in further development of the MohsAIQ database with the American College of Mohs Surgery (ACMS). Dr. Given served as the Resident Representative to the Board of Directors for the ASDS/ASDSA (2019-2021) and is a Contributing Editor to the peer-reviewed journal Dermatologic Surgery. Dr. Given is an active member of AAD, ASDS, ACMS and the AMA.
Dr. Given received her MBA in Managerial Organization and Entrepreneurship from the University of Chicago Booth School of Business. She worked as an Innovation Fellow through the Polsky Center at UChicago, supporting faculty new business and venture formation. She served as a graduate Teaching Assistant for Booth’s renowned Commercializing Innovation curriculum. She has served as a partner in G5 Partners LLC, a Silicon Valley-based, advisory, venture formation, and investment partnership, since 2014. Dr. Given serves a KOL and advisor for several device and imaging companies including Avita Medical, Enspectra, Retrouvé, and Portal Instruments.
Dr. Given has two sons and is an FAA-licensed pilot, with commercial, multi engine and instrument ratings.